Compare Five9 Inc (FIVN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs TG Therapeutics Inc — how do they compare? Five9 Inc trades at $36.4 (market cap $2.63B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 3.1× Five9 Inc's market cap, and Five9 Inc is more actively traded (1,864,393 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold Five9 Inc for 72 Days and TG Therapeutics Inc for 16 Days on average.
| FIVN | TGTX | |
|---|---|---|
Market Cap | $2.63B | $8.16B |
Volume | 1,864,393 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $38.65 | $59.06 |
52-Week Low | $13.61 | $26.94 |
Typical Hold Time | 72 Days | 16 Days |
Enterprise Value | $2.78B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $36.4, up 7.76% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. Revenue growth is accelerating, reaching $1.15B in 2025, while net income turned positive at $39.42M. The stock is near its 52-week high, supported by strong AI-driven subscription growth and leadership in the contact center-as-a-service market.
Outlook remains positive given robust AI revenue growth and raised guidance, but risks include high valuation multiples and insider selling. Analyst consensus is bullish with a $34 price target, though the current price exceeds it, suggesting near-term consolidation may occur before further upside.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
